The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > BUSINESS
BUSINESS
- AstraZeneca’s 2013 Payments to Healthcare Professionals Reach 7.5 Billion Yen
September 16, 2014
- JB, MTPC to Cease Sales Collaboration for Plasma Products in March 2015
September 16, 2014
- Takara Bio Pushes for Melanoma Drug Development with Eye on Fast Approval
September 12, 2014
- Shionogi Paid 15.2 Billion Yen to Medical Institutions in FY2013
September 12, 2014
- LEO Pharma Launches Its 1st Product in Japan, with Kyowa Kirin as Distributor
September 12, 2014
- Nobelpharma Collaborates with US Research Institute for Development of Endometriosis Treatment
September 12, 2014
- US FDA Approves Xtandi for Chemotherapy-Naïve Patients with Metastatic CRPC: Astellas
September 12, 2014
- Sawai to Comarket Sandoz’s Filgrastim Biosimilar
September 11, 2014
- Eisai Partners with Kyorin for Utilization of Eisai's Compound Library in Antibacterial Field
September 11, 2014
- Eli Lilly Japan, Hitachi Ink Sales Deal for Radiopharmaceutical Synthesizer for AD-Related Protein Imaging in Japan
September 10, 2014
- Shionogi to Realign Japan Sales Teams, Heed Regional Demands
September 10, 2014
- Zeria’s PMS Treatment Prefemin Now on Sale as “Drug Requiring Guidance”
September 10, 2014
- Janssen Discloses 2013 Payments of 8.3 Billion Yen to Healthcare Professionals
September 10, 2014
- Otsuka to Launch Deltyba on September 26; Launch Delayed in Anticipation of Revised TB Treatment Guidelines
September 10, 2014
- Medical & Biological Lab Seeking Partner for Dengue Fever Drug Development
September 9, 2014
- Announcement: Sales Excellence Japan 2014 to Be Held on October 14, 15
September 9, 2014
- Ethical Drug Sales Down 3.0% in July: Crecon Report
September 9, 2014
- Ono, Bristol-Myers Sue Merck over Anti-PD-1 Antibody Patent
September 9, 2014
- Chugai Launches ALK Inhibitor Alecensa
September 9, 2014
- Pfizer Japan, Astellas to Terminate Copromotion Deal for Caduet in March Next Year
September 9, 2014
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…